Back

Sodium-glucose cotransporter 2 inhibitor enhances mitochondrial stress resistance without altering ATP production in patients with ST-elevation myocardial infarction

30 August 2026 (12:15 - 12:45)
Organised by: Logo
Congress Presentation Part of: Innovations in post-infarction care: cardiometabolic, molecular, and haemodynamic approaches Pharmacotherapy ESC Professional Premium Access ESC Congress 2026 European Society of Cardiology

About the speaker

Photo
Miss Nattayaporn Apaijai

Chiang Mai University, Chiang Mai (Thailand)

3 More presentations in this session

Presentation thumbnail
Beta blockers and renin-angiotensin-aldosterone system inhibitors after type 2 myocardial infarction, a target trial emulation study
Doctor A. Gard (Uppsala, SE)
Abstract Slides Video
Presentation thumbnail
Hemodynamic impact of low-dose dobutamine in patients with acute myocardial infarction at risk of cardiogenic shock – a randomized clinical trial
Doctor S. Holle (Copenhagen, DK)
Abstract Slides Video
Presentation thumbnail
Comparison of oxidative and tissue stress biomarkers and platelet activation in myocardial infarction treated with prasugrel or ticagrelor
Doctor T. Vichova (Prague, CZ)
Abstract Slides Video

Access the full session

Session thumbnail
Innovations in post-infarction care: cardiometabolic, molecular, and haemodynamic approaches

The Event

Event poster

ESC Congress 2026

30 August 2026 12:15 CET
You may be interested in
thumbnail
Congress Presentation
Potential cardio-protective role of dapagliflozin in diabetic patients presented with anterior ST-elevation myocardial infarction (STEMI).
13 May 2024
thumbnail
Congress Presentation
Effects of sodium glucose co-transporter-2 inhibitor on atrial tachyarrhythmia burden in patients with cardiovascular implantable electronic device
7 April 2024
thumbnail
Congress Presentation
Cardiovascular proton magnetic resonance spectroscopy to distinguish between infarct and non-infarct region after ST-segment elevation myocardial infarction
28 August 2026
thumbnail
Congress Presentation
Prognostic outcomes of SGLT2 inhibitors versus metformin in patients with type 2 diabetes and acute myocardial infarction
29 August 2026

ESC 365 is supported by

novartis Explore sponsored resources
novo-nordisk Explore sponsored resources

ESC 365 is supported by

novartis Explore sponsored resources
novo-nordisk Explore sponsored resources